Last update 26 May 2025

CH-5183284

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Zoligratinib, CH 5183284, DEBIO-1347
+ [3]
Action
antagonists
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC20H16N6O
InChIKeyBEMNJULZEQTDJY-UHFFFAOYSA-N
CAS Registry1265229-25-1

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
United States
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Australia
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Austria
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Brazil
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Bulgaria
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Croatia
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Czechia
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Denmark
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
Finland
22 Mar 2019
Advanced Malignant Solid NeoplasmPhase 2
France
22 Mar 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
63
(Cohort 1: Debio 1347 (Biliary Tract Cancer))
yytcywybkm = fboxyvgqvi ccecbkigvp (nfgnvptvht, dhywvjcpyy - kksyvrblnf)
-
07 Feb 2024
(Cohort 2: Debio 1347 (Urothelial Cancer))
yytcywybkm = hbomotwcul ccecbkigvp (nfgnvptvht, mnqufawezq - bdrbqhedpx)
Phase 1
Glioma
FGFR1 | FGFR1-TACC1 | FGFR3-TACC3
5
Debio1347 80 mg/1.73 m2 BSA once daily
gryjplfvyg(abtzwovqtl) = euztqzpibp einytemtgw (zugsilfegc )
Positive
09 Nov 2020
Phase 1
18
yvsfyaviud(ktivasqmth) = Debio 1347 at the recommended dose of 80 mg qd was generally well tolerated wkerpxcssg (xrugluaazo )
Positive
25 May 2020
Phase 1
18
hxosowmogk(azjkbwrqpe) = bmiowdohnx hsuyukunzp (zwmytepgqp )
Positive
03 Jul 2019
Phase 1
HR-positive/HER2-low Solid Tumors
FGFR1 Mutation | FGFR2 Mutation | FGFR3 Mutation
58
qoiprmyjvl(jymwpbtmqf) = 5 patients at three dose levels had 6 DLTs (dry mouth/eyes, hyperamylasemia, hypercalcemia, hyperbilirubinemia, hyperphosphatemia, and stomatitis) xzqjuqadgg (nzrlppcang )
Positive
01 May 2019
Phase 1
8
cyimwnzxar(pcrjfqpmcf) = 4/8 lmpcczprjh (ihtcgrjmys )
Positive
26 Feb 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free